Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?
Theriva Biologics shares surged 92% to $0.84 on Oct. 15 after reporting its VCN-01 plus chemotherapy met primary survival endpoints in metastatic pancreatic cancer, prompting a planned Phase 3 trial. The company will present expanded VIRAGE Phase 2b data at ESMO 2025 and interim SYN-004 safety results at IDWeek 2025. Theriva held $12.1 million in cash as of June 30, with a $7.5 million offering closed in May.
